The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate
Open accessAbstract
The relative importance of the different proteolytic sites in mammalian proteasomes in protein degradation has not been studied systematically. Nevertheless, it is widely assumed that inhibition of the chymotrypsin-like site, the primary target of the proteasome inhibitors used in research and cancer therapy, reflects the degree of inhibition of protein breakdown. Here we demonstrate that selective inactivation of the chymotrypsin-like site reduced degradation of model proteins by pure 26 S proteasomes by only 11-50% and decreased only slightly the breakdown of proteins in HeLa cells. Inactivation of the caspase-like site decreased breakdown of model proteins by 12-22% and of the trypsin-like site by 3-35%. The relative contributions of these different sites depended on the protein substrate, and the importance of the trypsin-like sites depended on the substrate's content of basic residues. Simultaneous inhibition of the chymotrypsin-like and the caspase- or trypsin-like sites was needed to reduce degradation by >50%. Thus, 1) all three types of active sites contribute significantly to protein breakdown, 2) their relative importance varies widely with the substrate, 3) assaying the chymotrypsin-like activity overestimates the actual reduction in protein degradation, and 4) inhibition of multiple sites is required to markedly decrease proteolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Udenfriend, S., Stein, S., Böhlen, P., Dairman, W., Leimgruber, W., & Weigele, M. (1972) · Science · doi:10.1126/science.178.4063.871 · Cited by 2,649
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis
Voges, D., Zwickl, P., & Baumeister, W. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.1015 · Cited by 1,608
The Proteasome: Paradigm of a Self-Compartmentalizing Protease
Baumeister, W., Walz, J., Zühl, F., & Seemüller, E. (1998) · Cell · doi:10.1016/s0092-8674(00)80929-0 · Cited by 1,494
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Self-citationDEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
Rock, K. L., & Goldberg, A. L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.739 · Cited by 921
Self-citationMolecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Proteasomes and their kin: proteases in the machine age
Pickart, C. M., & Cohen, R. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1336 · Cited by 735
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
The Sizes of Peptides Generated from Protein by Mammalian 26 and 20 S Proteasomes
Kisselev, A. F., Akopian, T. N., Woo, K. M., & Goldberg, A. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3363 · Cited by 573
Self-citationγ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes
Gaczynska, M., Rock, K. L., & Goldberg, A. L. (1993) · Nature · doi:10.1038/365264a0 · Cited by 570
Self-citationHeinemeyer, W., Fischer, M., Krimmer, T., Stachon, U., & Wolf, D. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25200 · Cited by 519
The proteasome as a target for cancer therapy.
Voorhees, P. M., Dees, E. C., O’Neil, B. H., & Orlowski, R. Z. (2003) · PubMed · Cited by 455
Chen, P., & Hochstrasser, M. (1996) · Cell · doi:10.1016/s0092-8674(00)80171-3 · Cited by 404
Craiu, A., Gaczynska, M., Akopian, T., Gramm, C. F., Fenteany, G., Goldberg, A. L., & Rock, K. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.13437 · Cited by 382
Self-citationMonitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic Peptide Substrates
Kisselev, A. F., & Goldberg, A. L. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)98030-0 · Cited by 346
Self-citationProtein degradation and the generation of MHC class I-presented peptides
Rock, K. L., York, I. A., Saric, T., & Goldberg, A. L. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80012-8 · Cited by 339
Self-citation26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide
Cascio, P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.10.2357 · Cited by 330
Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1
Nussbaum, A. K., Dick, T. P., Keilholz, W., Schirle, M., Stevanović, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D. H., Huber, R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12504 · Cited by 311
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Arendt, C. S., & Hochstrasser, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7156 · Cited by 302
Proteasome Inhibitors Activate Stress Kinases and Induce Hsp72
Meriin, A. B., Gabai, V. L., Yaglom, J., Shifrin, V. I., & Sherman, M. Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6373 · Cited by 300
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L., Ovaa, H., & Galardy, P. J. (2005) · Nature Methods · doi:10.1038/nmeth759 · Cited by 262
Reits, E., Neijssen, J., Herberts, C., Benckhuijsen, W., Janssen, L., Drijfhout, J. W., & Neefjes, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00074-3 · Cited by 261
Dick, T. P., Nussbaum, A. K., Deeg, M., Heinemeyer, W., Groll, M., Schirle, M., Keilholz, W., Stevanović, S., Wolf, D. H., Huber, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25637 · Cited by 260
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. (2000) · Worldwide Protein Data Bank · doi:10.2210/pdb1g65/pdb · Cited by 253
Kisselev, A. F., Akopian, T. N., & Goldberg, A. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.1982 · Cited by 212
Self-citationLandowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., & Dorr, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3684 · Cited by 202
Akopian, T. N., Kisselev, A. F., & Goldberg, A. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.3.1791 · Cited by 201
Self-citationKisselev, A. F., Garcia-Calvo, M., Overkleeft, H. S., Peterson, E., Pennington, M. W., Ploegh, H. L., Thornberry, N. A., & Goldberg, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303725200 · Cited by 191
Self-citationKisselev, A. F., Kaganovich, D., & Goldberg, A. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112360200 · Cited by 180
Self-citationNazif, T., & Bogyo, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061028898 · Cited by 179
Šarić, T., Beninga, J., Graef, C. I., Akopian, T. N., Rock, K. L., & Goldberg, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105517200 · Cited by 173
Self-citationIntracellular distribution of proteasomes
Rivett, A. J. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80040-x · Cited by 158
Effects of PS-341 on the Activity and Composition of Proteasomes in Multiple Myeloma Cells
Altun, M., Galardy, P. J., Shringarpure, R., Hideshima, T., LeBlanc, R., Anderson, K. C., Ploegh, H. L., & Kessler, B. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0506 · Cited by 153
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
Adams, J. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00343-5 · Cited by 150
FUERTES, G., DE LLANO, J. J. M., VILLARROYA, A., RIVETT, A. J., & KNECHT, E. (2003) · Biochemical Journal · doi:10.1042/bj20030282 · Cited by 149
Shamu, C. E., Story, C. M., Rapoport, T. A., & Ploegh, H. L. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.1.45 · Cited by 148
PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication
Chauhan, D., Hideshima, T., & Anderson, K. C. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100037 · Cited by 146
Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors
Myung, J., Kim, K. B., Lindsten, K., Dantuma, N. P., & Crews, C. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00188-5 · Cited by 128
The ATP dependence of the degradation of short- and long-lived proteins in growing fibroblasts.
Gronostajski, R. M., Pardee, A. B., & Goldberg, A. L. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)83626-8 · Cited by 116
Self-citationVinitsky, A., Cardozo, C. P., Sepp‐Lorenzino, L., Michaud, C., & Orłowski, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43960-9 · Cited by 111
Substrate specificity of the human proteasome
Harris, J. L., Alper, P. B., Li, J., Rechsteiner, M., & Backes, B. J. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00080-1 · Cited by 110
Tarcsa, E., Szymańska, G., Lecker, S. H., O’Connor, C. M., & Goldberg, A. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001555200 · Cited by 110
Self-citationHamilton, A. L., Eder, J. P., Pavlick, A. C., Clark, J. W., Liebes, L., García‐Carbonero, R., Chachoua, A., Ryan, D. P., Soma, V., Farrell, K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.136 · Cited by 103
Groll, M., Nazif, T. M., Huber, R., & Bogyo, M. S. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00144-8 · Cited by 84
Cardozo, C. P., & Michaud, C. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00493-9 · Cited by 80
Proteasomes: The World of Regulatory Proteolysis
Hilt, W. (2000) · CRC Press eBooks · doi:10.1201/9781498713184 · Cited by 76
Oberdorf, J. A., Carlson, E. J., & Skach, W. R. (2001) · Biochemistry · doi:10.1021/bi011322y · Cited by 41
Cited by
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Muchamuel, T., Basler, M., Aujay, M. A., Suzuki, E., Kalim, K. W., Lauer, C., Sylvain, C., Ring, E. R., Shields, J., Jiang, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1978 · Cited by 599
Regulation of CD8 + T Cell Development by Thymus-Specific Proteasomes
Murata, S., Sasaki, K., Kishimoto, T., Niwa, S.-I., Hayashi, H., Takahama, Y., & Tanaka, K. (2007) · Science · doi:10.1126/science.1141915 · Cited by 580
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Self-citationOerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
Metadata
- Authors
- Kisselev, A. F., Callard, A., & Goldberg, A. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 281
- Issue
- 13
- Pages
- 8582-8590
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2049743082
- Cited by
- 416
- References
- 52
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.